Pfizer has announced their appointment of Ben Osborn as managing director in the UK, taking over from Erik Nordkamp, who will now become general manager UK and cluster lead Europe within Pfizer’s Established Medicines business.
Ben has been a part of Pfizer for 20 years, most recently leading the marketing organisation within Pfizer’s Innovative Medicines business at a regional level since 2015.
Prior to this, he was head of Pfizer Oncology in the UK, where he assisted in shaping UK cancer policy through his work with Government, patient groups and as a co-chair of the ABPI’s cancer group.
Commenting on his appointment, Ben said: “I am delighted to be returning to the UK business and to be taking on the role of UK Managing Director at such an important time. With the NHS at a critical moment in the development of its long-term plan, a new era of partnership between the health service and industry will be vital to achieving the best for UK patients. We are, therefore, very keen to develop new and build on existing relationships with Government and the NHS to try and help deliver this”.
Ben will be filling the shoes of Erik Nordkamp, who has successfully led the UK Company for almost four years. During this time, he has also chaired the American Pharmaceutical Group (APG) and is serving as President of the Association of the British Pharmaceutical Industry (ABPI). Erik continues to be based in the UK and will remain as ABPI President until April 2019, when the ABPI’s next Annual General Meeting takes place.
